| 1800 | Humans (MeSH) |
| 1247 | SARS-CoV-2 (MeSH) |
| 1063 | COVID-19 (MeSH) |
| 1005 | Pandemics (MeSH) |
| 876 | Hydroxychloroquine (therapeutic use) |
| 771 | Coronavirus Infections (drug therapy) |
| 629 | Pneumonia, Viral (drug therapy) |
| 615 | Male (MeSH) |
| 601 | Female (MeSH) |
| 580 | COVID-19 (drug therapy) |
| 544 | Betacoronavirus (MeSH) |
| 525 | Antiviral Agents (therapeutic use) |
| 479 | Middle Aged (MeSH) |
| 406 | Aged (MeSH) |
| 353 | Adult (MeSH) |
| 339 | Hydroxychloroquine (adverse effects) |
| 321 | Treatment Outcome (MeSH) |
| 270 | Coronavirus Infections (epidemiology) |
| 264 | Pneumonia, Viral (epidemiology) |
| 231 | Hydroxychloroquine (administration & dosage) |
| 224 | Azithromycin (therapeutic use) |
| 212 | Chloroquine (therapeutic use) |
| 193 | Betacoronavirus (drug effects) |
| 191 | Retrospective Studies (MeSH) |
| 190 | Coronavirus Infections (complications) |
| 183 | Pneumonia, Viral (complications) |
| 174 | Pneumonia, Viral (virology) |
| 172 | Coronavirus Infections (diagnosis) |
| 167 | Pneumonia, Viral (diagnosis) |
| 166 | Coronavirus Infections (virology) |
| 166 | Coronavirus Infections (therapy) |
| 158 | Pneumonia, Viral (therapy) |
| 157 | Drug Therapy, Combination (MeSH) |
| 157 | Antiviral Agents (adverse effects) |
| 154 | COVID-19 (epidemiology) |
| 152 | Drug Combinations (MeSH) |
| 149 | Aged, 80 and over (MeSH) |
| 148 | Antimalarials (therapeutic use) |
| 142 | Hydroxychloroquine (MeSH) |
| 136 | Alanine (analogs & derivatives) |
| 136 | Adenosine Monophosphate (analogs & derivatives) |
| 132 | Lopinavir (therapeutic use) |
| 131 | Ritonavir (therapeutic use) |
| 123 | COVID-19 (therapy) |
| 122 | Severity of Illness Index (MeSH) |
| 120 | Pandemics (prevention & control) |
| 120 | Hydroxychloroquine (pharmacology) |
| 118 | SARS-CoV-2 (drug effects) |
| 118 | Risk Factors (MeSH) |
| 117 | COVID-19 (virology) |
| 117 | Antiviral Agents (pharmacology) |
| 111 | Anti-Bacterial Agents (therapeutic use) |
| 110 | Antiviral Agents (administration & dosage) |
| 108 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 105 | Alanine (therapeutic use) |
| 105 | Adenosine Monophosphate (therapeutic use) |
| 103 | COVID-19 (complications) |
| 101 | Drug Repositioning (MeSH) |
| 101 | Chloroquine (adverse effects) |
| 100 | Coronavirus Infections (prevention & control) |
| 99 | Young Adult (MeSH) |
| 99 | Betacoronavirus (pathogenicity) |
| 98 | Hospitalization (MeSH) |
| 98 | Clinical Trials as Topic (MeSH) |
| 98 | Betacoronavirus (isolation & purification) |
| 95 | Pneumonia, Viral (MeSH) |
| 94 | Randomized Controlled Trials as Topic (MeSH) |
| 93 | Comorbidity (MeSH) |
| 92 | COVID-19 (mortality) |
| 91 | Pneumonia, Viral (mortality) |
| 91 | Azithromycin (adverse effects) |
| 89 | Coronavirus Infections (mortality) |
| 87 | Pneumonia, Viral (prevention & control) |
| 84 | Adolescent (MeSH) |
| 83 | Animals (MeSH) |
| 79 | COVID-19 (diagnosis) |
| 74 | Coronavirus Infections (physiopathology) |
| 73 | Pneumonia, Viral (physiopathology) |
| 73 | Coronavirus Infections (immunology) |
| 72 | Azithromycin (administration & dosage) |
| 70 | Pneumonia, Viral (immunology) |
| 69 | Long QT Syndrome (chemically induced) |
| 69 | Antirheumatic Agents (therapeutic use) |
| 67 | Child (MeSH) |
| 65 | COVID-19 Testing (MeSH) |
| 61 | Tomography, X-Ray Computed (MeSH) |
| 61 | Time Factors (MeSH) |
| 61 | Enzyme Inhibitors (therapeutic use) |
| 61 | COVID-19 (prevention & control) |
| 60 | Risk Assessment (MeSH) |
| 60 | Intensive Care Units (MeSH) |
| 58 | Antimalarials (adverse effects) |
| 57 | Chloroquine (pharmacology) |
| 56 | SARS-CoV-2 (isolation & purification) |
| 56 | Respiration, Artificial (MeSH) |
| 56 | COVID-19 (physiopathology) |
| 52 | United States (MeSH) |
| 52 | Prognosis (MeSH) |
| 49 | COVID-19 (immunology) |
| 49 | Azithromycin (MeSH) |
| 48 | Immunization, Passive (MeSH) |
| 48 | Glucocorticoids (therapeutic use) |
| 47 | Betacoronavirus (immunology) |
| 46 | SARS-CoV-2 (pathogenicity) |
| 46 | Prospective Studies (MeSH) |
| 45 | Immunologic Factors (therapeutic use) |
| 45 | Chloroquine (administration & dosage) |
| 44 | Incidence (MeSH) |
| 44 | Hydroxychloroquine (pharmacokinetics) |
| 44 | Adrenal Cortex Hormones (therapeutic use) |
| 43 | Immunosuppressive Agents (therapeutic use) |
| 41 | Electrocardiography (MeSH) |
| 41 | Anticoagulants (therapeutic use) |
| 40 | Hospitalization (statistics & numerical data) |
| 40 | Coronavirus Infections (pathology) |
| 39 | Pneumonia, Viral (pathology) |
| 39 | Lung (diagnostic imaging) |
| 39 | Hospital Mortality (MeSH) |
| 39 | Drug Interactions (MeSH) |
| 38 | Anti-Inflammatory Agents (therapeutic use) |
| 37 | Coronavirus Infections (MeSH) |
| 37 | Cohort Studies (MeSH) |
| 37 | Child, Preschool (MeSH) |
| 36 | Transplant Recipients (MeSH) |
| 36 | Pneumonia, Viral (diagnostic imaging) |
| 36 | Age Factors (MeSH) |
| 35 | Pregnancy (MeSH) |
| 35 | Molecular Docking Simulation (MeSH) |
| 35 | Disease Progression (MeSH) |
| 35 | Coronavirus Infections (diagnostic imaging) |
| 35 | Clinical Laboratory Techniques (MeSH) |
| 35 | Antimalarials (administration & dosage) |
| 34 | Ritonavir (administration & dosage) |
| 34 | Pyrazines (therapeutic use) |
| 34 | Lopinavir (administration & dosage) |
| 34 | Betacoronavirus (physiology) |
| 34 | Angiotensin-Converting Enzyme 2 (MeSH) |
| 34 | Amides (therapeutic use) |
| 33 | Length of Stay (MeSH) |
| 33 | Italy (epidemiology) |
| 33 | COVID-19 (pathology) |
| 33 | Arrhythmias, Cardiac (chemically induced) |
| 32 | Infant (MeSH) |
| 32 | Drug Administration Schedule (MeSH) |
| 32 | Coronavirus Infections (transmission) |
| 31 | SARS-CoV-2 (physiology) |
| 31 | SARS-CoV-2 (genetics) |
| 31 | Ritonavir (adverse effects) |
| 31 | Pneumonia, Viral (transmission) |
| 31 | Lupus Erythematosus, Systemic (drug therapy) |
| 31 | Immunoglobulins, Intravenous (therapeutic use) |
| 31 | Antiviral Agents (pharmacokinetics) |
| 30 | Virus Replication (drug effects) |
| 30 | Spain (epidemiology) |
| 30 | SARS-CoV-2 (immunology) |
| 30 | Rheumatic Diseases (drug therapy) |
| 30 | Immunocompromised Host (MeSH) |
| 30 | Follow-Up Studies (MeSH) |
| 30 | Cross-Sectional Studies (MeSH) |
| 29 | Italy (MeSH) |
| 29 | Chloroquine (MeSH) |
| 29 | Antimalarials (pharmacology) |
| 28 | Practice Guidelines as Topic (MeSH) |
| 28 | Lopinavir (adverse effects) |
| 27 | United States (epidemiology) |
| 27 | China (MeSH) |
| 27 | Arthritis, Rheumatoid (drug therapy) |
| 26 | Pneumonia, Viral (blood) |
| 26 | Oxygen Inhalation Therapy (MeSH) |
| 26 | Azithromycin (pharmacology) |
| 25 | Immunosuppressive Agents (adverse effects) |
| 25 | Hydroxychloroquine (chemistry) |
| 25 | Drug Repositioning (methods) |
| 25 | Dose-Response Relationship, Drug (MeSH) |
| 25 | Betacoronavirus (genetics) |
| 25 | Angiotensin-Converting Enzyme Inhibitors (therapeutic use) |
| 24 | Viral Load (drug effects) |
| 24 | Survival Analysis (MeSH) |
| 24 | Infant, Newborn (MeSH) |
| 24 | Evidence-Based Medicine (MeSH) |
| 24 | Double-Blind Method (MeSH) |
| 24 | Critical Illness (MeSH) |
| 24 | Coronavirus Infections (blood) |
| 23 | Surveys and Questionnaires (MeSH) |
| 23 | Methylprednisolone (therapeutic use) |
| 23 | Long QT Syndrome (epidemiology) |
| 23 | Long QT Syndrome (diagnosis) |
| 23 | Fatal Outcome (MeSH) |
| 23 | Dexamethasone (therapeutic use) |
| 23 | COVID-19 Vaccines (MeSH) |
| 22 | Viral Load (MeSH) |
| 22 | Peptidyl-Dipeptidase A (metabolism) |
| 22 | Oseltamivir (therapeutic use) |
| 22 | Kidney Transplantation (MeSH) |
| 22 | Graft Rejection (prevention & control) |
| 22 | Electrocardiography (methods) |
| 22 | COVID-19 (blood) |
| 21 | Immunization, Passive (methods) |
| 21 | Hydroxychloroquine (blood) |
| 21 | Drug Therapy, Combination (methods) |
| 21 | Drug Synergism (MeSH) |
| 21 | Cytokine Release Syndrome (drug therapy) |
| 21 | Coronavirus Infections (metabolism) |
| 21 | Case-Control Studies (MeSH) |
| 21 | Anti-Bacterial Agents (adverse effects) |
| 20 | Off-Label Use (MeSH) |
| 20 | India (MeSH) |
| 20 | Hydroxychloroquine (supply & distribution) |
| 20 | Electrocardiography (drug effects) |
| 20 | Coronavirus (MeSH) |
| 20 | Combined Modality Therapy (MeSH) |
| 20 | Antiviral Agents (chemistry) |
| 19 | Torsades de Pointes (chemically induced) |
| 19 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 19 | France (MeSH) |
| 19 | Betacoronavirus (metabolism) |
| 19 | Anti-Infective Agents (adverse effects) |
| 18 | Spike Glycoprotein, Coronavirus (metabolism) |
| 18 | Pneumonia, Viral (metabolism) |
| 18 | Patient Safety (MeSH) |
| 18 | Anti-Infective Agents (therapeutic use) |
| 18 | Anti-Infective Agents (administration & dosage) |
| 17 | Spain (MeSH) |
| 17 | Sex Factors (MeSH) |
| 17 | Research Design (MeSH) |
| 17 | Pneumonia, Viral (etiology) |
| 17 | Pandemics (statistics & numerical data) |
| 17 | Nasopharynx (virology) |
| 17 | Molecular Dynamics Simulation (MeSH) |
| 17 | Health Personnel (MeSH) |
| 17 | Critical Care (MeSH) |
| 17 | COVID-19 Nucleic Acid Testing (MeSH) |
| 17 | COVID-19 (metabolism) |
| 17 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 16 | Uncertainty (MeSH) |
| 16 | Respiration, Artificial (methods) |
| 16 | Registries (MeSH) |
| 16 | India (epidemiology) |
| 16 | Disease Management (MeSH) |
| 16 | Computer Simulation (MeSH) |
| 16 | Cardiovascular Diseases (epidemiology) |
| 16 | Antirheumatic Agents (adverse effects) |
| 16 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 16 | Alanine (adverse effects) |
| 16 | Adenosine Monophosphate (adverse effects) |
| 15 | Vero Cells (MeSH) |
| 15 | Treatment Failure (MeSH) |
| 15 | Pre-Exposure Prophylaxis (MeSH) |
| 15 | Janus Kinase Inhibitors (therapeutic use) |
| 15 | Ivermectin (therapeutic use) |
| 15 | Immunosuppressive Agents (administration & dosage) |
| 15 | Host-Pathogen Interactions (MeSH) |
| 15 | Clinical Laboratory Techniques (methods) |
| 15 | Chloroquine (pharmacokinetics) |
| 15 | Chlorocebus aethiops (MeSH) |
| 15 | Biomarkers (blood) |
| 15 | Arrhythmias, Cardiac (diagnosis) |
| 15 | Alanine (administration & dosage) |
| 15 | Adenosine Monophosphate (administration & dosage) |
| 14 | Respiratory Distress Syndrome (drug therapy) |
| 14 | Receptors, Interleukin-6 (antagonists & inhibitors) |
| 14 | RNA, Viral (genetics) |
| 14 | Pregnancy Complications, Infectious (drug therapy) |
| 14 | Patient Selection (MeSH) |
| 14 | Intensive Care Units (statistics & numerical data) |
| 14 | Indoles (therapeutic use) |
| 14 | Global Health (MeSH) |
| 14 | Enoxaparin (therapeutic use) |
| 14 | Diagnosis, Differential (MeSH) |
| 14 | Cytokine Release Syndrome (virology) |
| 14 | Chemoprevention (MeSH) |
| 14 | Ceftriaxone (therapeutic use) |
| 14 | COVID-19 (transmission) |
| 14 | C-Reactive Protein (metabolism) |
| 14 | Anti-Bacterial Agents (administration & dosage) |
| 13 | United States Food and Drug Administration (MeSH) |
| 13 | Tomography, X-Ray Computed (methods) |
| 13 | Spike Glycoprotein, Coronavirus (genetics) |
| 13 | Spike Glycoprotein, Coronavirus (chemistry) |
| 13 | Rheumatic Diseases (epidemiology) |
| 13 | Renal Dialysis (MeSH) |
| 13 | Proportional Hazards Models (MeSH) |
| 13 | Observational Studies as Topic (MeSH) |
| 13 | Neoplasms (complications) |
| 13 | Mortality (MeSH) |
| 13 | Lupus Erythematosus, Systemic (complications) |
| 13 | Lung (pathology) |
| 13 | Length of Stay (statistics & numerical data) |
| 13 | Interferons (therapeutic use) |
| 13 | Hydroxychloroquine (toxicity) |
| 13 | Clinical Trials as Topic (methods) |
| 13 | Chloroquine (chemistry) |
| 13 | China (epidemiology) |
| 13 | Arthritis, Rheumatoid (complications) |
| 13 | Administration, Oral (MeSH) |
| 12 | Telemedicine (MeSH) |
| 12 | Survival Rate (MeSH) |
| 12 | Respiratory Insufficiency (therapy) |
| 12 | Respiration, Artificial (statistics & numerical data) |
| 12 | Pharmacovigilance (MeSH) |
| 12 | Peptidyl-Dipeptidase A (genetics) |
| 12 | Outpatients (MeSH) |
| 12 | Models, Biological (MeSH) |
| 12 | Lung (virology) |
| 12 | Long QT Syndrome (prevention & control) |
| 12 | Kidney Failure, Chronic (surgery) |
| 12 | Heparin, Low-Molecular-Weight (therapeutic use) |
| 12 | Extracorporeal Membrane Oxygenation (MeSH) |
| 12 | Drug Monitoring (methods) |
| 12 | Cardiovascular Diseases (chemically induced) |
| 12 | COVID-19 (diagnostic imaging) |
| 12 | Antibodies, Monoclonal (therapeutic use) |
| 11 | World Health Organization (MeSH) |
| 11 | Virus Internalization (drug effects) |
| 11 | Standard of Care (MeSH) |
| 11 | Ribavirin (therapeutic use) |
| 11 | Respiratory Distress Syndrome (virology) |
| 11 | Respiratory Distress Syndrome (etiology) |
| 11 | Prevalence (MeSH) |
| 11 | Pregnancy Complications, Infectious (virology) |
| 11 | Post-Exposure Prophylaxis (MeSH) |
| 11 | Outcome and Process Assessment, Health Care (MeSH) |
| 11 | Multicenter Studies as Topic (MeSH) |
| 11 | Malaria (drug therapy) |
| 11 | Lysosomes (drug effects) |
| 11 | Lung (drug effects) |
| 11 | Long QT Syndrome (physiopathology) |
| 11 | Logistic Models (MeSH) |
| 11 | Kidney Failure, Chronic (therapy) |
| 11 | Intubation, Intratracheal (MeSH) |
| 11 | Interleukin-6 (immunology) |
| 11 | Interleukin 1 Receptor Antagonist Protein (therapeutic use) |
| 11 | Inflammation (MeSH) |
| 11 | Immunomodulation (MeSH) |
| 11 | Hydroxychloroquine (metabolism) |
| 11 | France (epidemiology) |
| 11 | Fever (etiology) |
| 11 | Disease Outbreaks (MeSH) |
| 11 | Disease Models, Animal (MeSH) |
| 11 | Deprescriptions (MeSH) |
| 11 | Darunavir (therapeutic use) |
| 11 | Arrhythmias, Cardiac (epidemiology) |
| 11 | Antirheumatic Agents (administration & dosage) |
| 11 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
| 11 | Anti-Inflammatory Agents (pharmacology) |
| 11 | Angiotensin Receptor Antagonists (therapeutic use) |
| 11 | Alanine (pharmacology) |
| 11 | Adenosine Monophosphate (pharmacology) |
| 10 | Viral Vaccines (MeSH) |
| 10 | Steroids (therapeutic use) |
| 10 | Rheumatic Diseases (complications) |
| 10 | Retinal Diseases (chemically induced) |
| 10 | Outcome Assessment, Health Care (MeSH) |
| 10 | Odds Ratio (MeSH) |
| 10 | New York City (MeSH) |
| 10 | Neoplasms (drug therapy) |
| 10 | Mice (MeSH) |
| 10 | Kidney Transplantation (adverse effects) |
| 10 | Kidney Failure, Chronic (complications) |
| 10 | Kaplan-Meier Estimate (MeSH) |
| 10 | Inpatients (MeSH) |
| 10 | Host-Pathogen Interactions (drug effects) |
| 10 | Drug Therapy, Combination (adverse effects) |
| 10 | Drug Monitoring (MeSH) |
| 10 | Databases, Factual (MeSH) |
| 10 | Cytokines (blood) |
| 10 | Cytokine Release Syndrome (immunology) |
| 10 | Coronavirus 3C Proteases (MeSH) |
| 10 | Chloroquine (toxicity) |
| 10 | Cardiotoxicity (MeSH) |
| 10 | COVID-19 Vaccines (therapeutic use) |
| 10 | Binding Sites (MeSH) |
| 10 | Autoimmune Diseases (drug therapy) |
| 10 | Ascorbic Acid (therapeutic use) |
| 10 | Antiviral Agents (blood) |
| 10 | Antiviral Agents (MeSH) |
| 10 | Acute Generalized Exanthematous Pustulosis (etiology) |
| 9 | Sulfonamides (therapeutic use) |
| 9 | Spike Glycoprotein, Coronavirus (antagonists & inhibitors) |
| 9 | Ritonavir (pharmacology) |
| 9 | Risk (MeSH) |
| 9 | Rheumatologists (MeSH) |
| 9 | Protein Binding (MeSH) |
| 9 | Protease Inhibitors (pharmacology) |
| 9 | Pregnancy Complications, Infectious (therapy) |
| 9 | Politics (MeSH) |
| 9 | New York City (epidemiology) |
| 9 | Lupus Erythematosus, Systemic (epidemiology) |
| 9 | Lopinavir (pharmacology) |
| 9 | Iran (MeSH) |
| 9 | Interleukin-6 (antagonists & inhibitors) |
| 9 | Interferon beta-1a (therapeutic use) |
| 9 | Immunologic Factors (pharmacology) |
| 9 | Immunologic Factors (adverse effects) |
| 9 | Hypoxia (therapy) |
| 9 | Hypertension (epidemiology) |
| 9 | Host-Pathogen Interactions (immunology) |
| 9 | Host-Pathogen Interactions (genetics) |
| 9 | Glucosephosphate Dehydrogenase Deficiency (complications) |
| 9 | Fibrin Fibrinogen Degradation Products (metabolism) |
| 9 | Emergency Service, Hospital (MeSH) |
| 9 | Diabetes Mellitus (epidemiology) |
| 9 | Diabetes Mellitus (drug therapy) |
| 9 | Cytokines (immunology) |
| 9 | Cytokine Release Syndrome (etiology) |
| 9 | Compassionate Use Trials (MeSH) |
| 9 | Clinical Trials as Topic (statistics & numerical data) |
| 9 | Clinical Trials as Topic (standards) |
| 9 | COVID-19 (psychology) |
| 9 | Azetidines (therapeutic use) |
| 9 | Arrhythmias, Cardiac (physiopathology) |
| 9 | Arrhythmias, Cardiac (etiology) |
| 9 | Anti-Inflammatory Agents (adverse effects) |
| 9 | Ambulatory Care (MeSH) |
| 8 | Viral Nonstructural Proteins (metabolism) |
| 8 | Tumor Necrosis Factor Inhibitors (therapeutic use) |
| 8 | Symptom Assessment (MeSH) |
| 8 | Severe Acute Respiratory Syndrome (drug therapy) |
| 8 | Respiratory Insufficiency (etiology) |
| 8 | Respiratory Distress Syndrome (therapy) |
| 8 | Real-Time Polymerase Chain Reaction (MeSH) |
| 8 | Radiography, Thoracic (MeSH) |
| 8 | RNA, Viral (isolation & purification) |
| 8 | Protective Factors (MeSH) |
| 8 | Pregnancy Complications, Infectious (diagnosis) |
| 8 | Pre-Exposure Prophylaxis (methods) |
| 8 | Peptidyl-Dipeptidase A (immunology) |
| 8 | Oseltamivir (administration & dosage) |
| 8 | Neoplasms (mortality) |
| 8 | Models, Molecular (MeSH) |
| 8 | Lopinavir (MeSH) |
| 8 | Long QT Syndrome (drug therapy) |
| 8 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 8 | Immunosuppression (methods) |
| 8 | Immunosuppression (adverse effects) |
| 8 | Immunosuppression (MeSH) |
| 8 | Hypoxia (physiopathology) |
| 8 | Hypertension (complications) |
| 8 | HIV Infections (drug therapy) |
| 8 | Graft Rejection (immunology) |
| 8 | Fever (physiopathology) |
| 8 | Enzyme Inhibitors (adverse effects) |
| 8 | Endosomes (drug effects) |
| 8 | Dyspnea (etiology) |
| 8 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
| 8 | Drug Discovery (methods) |
| 8 | Drug Approval (MeSH) |
| 8 | Cytokines (metabolism) |
| 8 | Cytokine Release Syndrome (therapy) |
| 8 | Critical Illness (therapy) |
| 8 | Cough (physiopathology) |
| 8 | Cough (etiology) |
| 8 | Chloroquine (analogs & derivatives) |
| 8 | Cardiovascular Diseases (complications) |
| 8 | COVID-19 (etiology) |
| 8 | Brazil (MeSH) |
| 8 | Autophagy (drug effects) |
| 8 | Anti-Inflammatory Agents (administration & dosage) |
| 8 | Angiotensin-Converting Enzyme 2 (metabolism) |
| 8 | Adrenal Cortex Hormones (adverse effects) |
| 7 | Viral Vaccines (therapeutic use) |
| 7 | Symptom Assessment (methods) |
| 7 | Spondylarthropathies (drug therapy) |
| 7 | Societies, Medical (MeSH) |
| 7 | SARS-CoV-2 (metabolism) |
| 7 | SARS-CoV-2 (enzymology) |
| 7 | SARS-CoV-2 (chemistry) |
| 7 | Ritonavir (MeSH) |
| 7 | Rheumatology (MeSH) |
| 7 | Research Design (standards) |
| 7 | Pyrazines (adverse effects) |
| 7 | Protease Inhibitors (therapeutic use) |
| 7 | Polymerase Chain Reaction (MeSH) |
| 7 | Personal Protective Equipment (MeSH) |
| 7 | Neoplasms (virology) |
| 7 | Multivariate Analysis (MeSH) |
| 7 | Molecular Targeted Therapy (MeSH) |
| 7 | Models, Theoretical (MeSH) |
| 7 | Lysosomes (metabolism) |
| 7 | Interferon beta-1b (therapeutic use) |
| 7 | Hypoglycemic Agents (therapeutic use) |
| 7 | Hypertension (drug therapy) |
| 7 | Hospitals (MeSH) |
| 7 | Heparin (therapeutic use) |
| 7 | Hemolysis (MeSH) |
| 7 | Heart Diseases (chemically induced) |
| 7 | Fever (virology) |
| 7 | Ferritins (blood) |
| 7 | Drug Evaluation, Preclinical (MeSH) |
| 7 | Drug Eruptions (etiology) |
| 7 | Drug Development (MeSH) |
| 7 | Delivery of Health Care (MeSH) |
| 7 | Cytokines (antagonists & inhibitors) |
| 7 | Critical Care (methods) |
| 7 | Coronavirus Infections (genetics) |
| 7 | Coronavirus (isolation & purification) |
| 7 | Coronavirus (genetics) |
| 7 | Communication (MeSH) |
| 7 | Coinfection (MeSH) |
| 7 | Cause of Death (MeSH) |
